Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data.

Basal insulin is often prescribed to patients with sub-optimally controlled type 2 diabetes (T2D); however, its therapeutic efficacy is inadequate in many. During the MOBILE study's baseline phase, we evaluated 173 participants' continuous glucose monitoring (CGM) data (mean±SD age 57±9 years; 50% female; glycated hemoglobin 9.1% [range, 7.1-11.6%]; 40% using sulfonylureas; 19% using NPH; reported self-monitored blood glucose [SMBG] frequency median 1.0 checks/day) who were using basal, but not prandial insulin. Blinded CGM data were recorded for 10 days prior to randomization. Mean glucose value was 208±47 mg/dL and lowest in the early morning. Mean time in the 70-180 mg/dL range was 9.6±6.1 h/day (40%±25%). Hyperglycemia was extensive with medians of 14.7 (61%) and 5.0 (20.9%) h/day with glucose >180 and >250 mg/dL, respectively. Hypoglycemia was infrequent (median [IQR] 0 [0, 4.3] minutes/day (0.0% [0.0%, 0.3%]) with glucose <70 mg/dL). Blinded CGM highlights limitations of infrequent SMBG in T2D basal insulin users and allows characterization of hyperglycemia and hypoglycemia in basal insulin users with suboptimal control. The MOBILE study randomized phase will define the benefits of using real-time CGM compared to SMBG in this population. This article is protected by copyright. All rights reserved.